Table 1.
Blood ANGP-2 measurement profiles of the study participants. The results are provided as means ± SDs
| Healthy volunteers (HVs) | Hepatitis C virus ( +) (HCV) patients | |
|---|---|---|
| Number | 15 | 20 |
| Age (median, range) | 26 (21–47) | 70 (38–84) |
| Gender (M/F) | 2/13 | 11/9 |
| Glecaprevir + Pibrentasvir | – | 14 |
| Ledipasvir + Sofosbuvir | – | 5 |
| Elbasvir + Grazopervir | – | 1 |
| ANGP-2 (pg/mL) | 1896 ± 771.7 | 3115 ± 1116 |
| M2BPGi (c. o. i.) | N. A | 3.56 ± 3.25 |
| VTQ (m/s) | N. A | 1.74 ± 0.80 |
| PLT (× 104/μL) | N. A | 14.9 ± 5.7 |
| ALBI score | N. A | – 2.667 ± 0.3693 |
| PT (INR) | N. A | 1.04 ± 0.09 |
| Albumin | N. A | 4 ± 0.4 |
| ALT (IU/L) | N. A | 48.80 ± 37.65 |
| AFP (ng/mL) | N. A | 15.4 ± 34.2 |
| DCP (mAU/mL) | N. A | 20.2 ± 9.5 |
| Pathological examination | N. A | 14 |
|
Metavir F-stage F0/F1/F2/F3/F4 |
0/6/4/1/3 |
ANGP-2; angiopoietin-2; VTQ, virtual touch quantification; PLT, platelet; ALBI score, albumin bilirubin score; PT, prothrombin time; ALT, alanine transaminase; AFP, alpha-fetoprotein; DCP, des-γ-carboxy prothrombin